Chameleon Biosciences is developing a re-dosable gene therapy using adeno-associated virus (AAV) technology to provide targeted and repeatable treatment options for genetic disorders. This approach addresses the limitations of traditional gene therapies, which often require a single administration and lack flexibility in treatment regimens.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional gene therapies using adeno-associated virus (AAV) vectors typically allow for a single administration, limiting treatment flexibility and the ability to adjust dosages over time. This inflexibility poses challenges for managing genetic disorders that require long-term or adaptive treatment regimens.
Solution
Chameleon Biosciences is developing a re-dosable gene therapy platform based on AAV technology, enabling targeted and repeatable treatment options for genetic disorders. This approach overcomes the limitations of single-administration gene therapies by allowing for multiple doses, providing clinicians with the ability to fine-tune treatment regimens and address potential waning of therapeutic effects. The company's technology aims to improve long-term efficacy and safety profiles for patients with genetic diseases.
Target Audience
The primary target audience includes patients with genetic disorders who require long-term or adaptive gene therapy treatments, as well as clinicians specializing in gene therapy and genetic diseases.
Features
- Re-dosable AAV vectors for sustained therapeutic effect
- Targeted gene delivery to specific tissues or cell types
- Enhanced safety profile through controlled vector administration
- Potential for personalized treatment regimens based on individual patient needs